33
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Positron Emission Tomography as a Method for Measuring Drug Delivery to Tumors in vivo: The Example of [ 11C]docetaxel

      review-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Systemic anticancer treatments fail in a substantial number of patients. This may be caused by inadequate uptake and penetration of drugs in malignant tumors. Consequently, improvement of drug delivery to solid tumors may enhance its efficacy. Before evaluating strategies to enhance drug uptake in tumors, better understanding of drug delivery to human tumors is needed. Positron emission tomography (PET) is an imaging technique that can be used to monitor drug pharmacokinetics non-invasively in patients, based on radiolabeling these drugs with short-lived positron emitters. In this mini review, principles and potential applications of PET using radiolabeled anticancer drugs will be discussed with respect to personalized treatment planning in oncology. In particular, it will be discussed how these radiolabeled anticancer drugs could help to develop strategies for improved drug delivery to solid tumors. The development and clinical implementation of PET using radiolabeled anticancer drugs will be illustrated by validation studies of carbon-11 labeled docetaxel ([ 11C]docetaxel) in lung cancer patients.

          Related collections

          Most cited references36

          • Record: found
          • Abstract: not found
          • Article: not found

          On the origin of cancer cells.

          O WARBURG (1956)
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Molecular imaging of cancer with positron emission tomography.

            The imaging of specific molecular targets that are associated with cancer should allow earlier diagnosis and better management of oncology patients. Positron emission tomography (PET) is a highly sensitive non-invasive technology that is ideally suited for pre-clinical and clinical imaging of cancer biology, in contrast to anatomical approaches. By using radiolabelled tracers, which are injected in non-pharmacological doses, three-dimensional images can be reconstructed by a computer to show the concentration and location(s) of the tracer of interest. PET should become increasingly important in cancer imaging in the next decade.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy.

                Bookmark

                Author and article information

                Journal
                Front Oncol
                Front Oncol
                Front. Oncol.
                Frontiers in Oncology
                Frontiers Media S.A.
                2234-943X
                26 June 2013
                13 August 2013
                2013
                : 3
                : 208
                Affiliations
                [1] 1Department of Internal Medicine, VU University Medical Center , Amsterdam, Netherlands
                [2] 2Department of Radiology and Nuclear Medicine, VU University Medical Center , Amsterdam, Netherlands
                [3] 3Department of Pulmonary Diseases, VU University Medical Center , Amsterdam, Netherlands
                Author notes

                Edited by: Fabrizio Marcucci, Istituto Superiore di Sanità, Italy

                Reviewed by: Amit K. Tiwari, Tuskegee University, USA; Matteo Bellone, San Raffaele Scientific Institute, Italy

                *Correspondence: Astrid A. M. van der Veldt, Department of Internal Medicine, VU University Medical Center, P.O. Box 7057, 1007 MB Amsterdam, Netherlands e-mail: aam.vanderveldt@ 123456vumc.nl

                This article was submitted to Frontiers in Pharmacology of Anti-Cancer Drugs, a specialty of Frontiers in Oncology.

                Article
                10.3389/fonc.2013.00208
                3742054
                23986880
                fcddc712-9feb-4635-9712-329366cdeff7
                Copyright © 2013 van der Veldt, Smit and Lammertsma.

                This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

                History
                : 31 May 2013
                : 30 July 2013
                Page count
                Figures: 8, Tables: 0, Equations: 0, References: 38, Pages: 7, Words: 4882
                Categories
                Oncology
                Review Article

                Oncology & Radiotherapy
                positron emission tomography,radiolabeled anticancer drugs,drug delivery,tumors,[11c]docetaxel,lung cancer

                Comments

                Comment on this article